Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring

Edoardo Francini ¹, Pier Vitale Nuzzo ², Giuseppe Nicolò Fanelli ³

⁰Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Cancers +

|

February 10, 2024

View abstract on PubMed

Summary

Cell-free DNA (cfDNA) shows promise as a biomarker for solid cancers. Ongoing research highlights its potential in predicting patient outcomes and guiding treatment decisions.

Area Of Science

Oncology
Molecular Biology
Biochemistry

Background

Cell-free DNA (cfDNA) analysis is emerging as a powerful tool in oncology.
This Special Issue compiles 21 articles exploring cfDNA's role in solid tumors.

Discussion

cfDNA serves as both a prognostic and predictive biomarker.
Research indicates cfDNA's utility in monitoring cancer progression and treatment response.

Key Insights

The field of cfDNA research in solid cancers is rapidly advancing.
Multiple studies demonstrate the clinical relevance of cfDNA biomarkers.

Outlook

Future research will likely focus on standardizing cfDNA assays.
Integration of cfDNA analysis into routine clinical practice is anticipated.